Johnson & Johnson (JNJ) Given Consensus Rating of “Hold” by Analysts

Shares of Johnson & Johnson (NYSE:JNJ) have earned a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $142.41.

Several analysts have issued reports on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 16th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price target (down previously from $175.00) on shares of Johnson & Johnson in a report on Wednesday, April 18th. They noted that the move was a valuation call. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Wednesday, April 18th. Finally, Deutsche Bank reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 18th.

NYSE JNJ traded down $0.72 on Thursday, hitting $129.50. The stock had a trading volume of 4,542,700 shares, compared to its average volume of 7,173,572. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. The stock has a market capitalization of $350.79 billion, a PE ratio of 17.81, a P/E/G ratio of 1.99 and a beta of 0.73.



Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the prior year, the company posted $1.83 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. research analysts anticipate that Johnson & Johnson will post 8.14 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.78%. The ex-dividend date of this dividend is Monday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

Hedge funds have recently added to or reduced their stakes in the stock. Goodman Financial Corp purchased a new stake in Johnson & Johnson during the 4th quarter valued at $104,000. Financial Gravity Wealth Inc. purchased a new stake in Johnson & Johnson during the 1st quarter valued at $105,000. CSat Investment Advisory L.P. purchased a new stake in Johnson & Johnson during the 2nd quarter valued at $107,000. Stelac Advisory Services LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at $108,000. Finally, WP Advisors LLC purchased a new stake in Johnson & Johnson during the 2nd quarter valued at $108,000. 66.20% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Leveraged Buyout (LBO) Explained

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply